Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Regulatory and Compliance Updates news
(page 11)
18 March 2026
Boliden invests SEK 4bn in Garpenberg hoist and SEK 1.5bn in Rönnskär SCM plant
SEK 4bn hoist at Garpenberg to keep 4.5 Mt/yr past 2030; SEK 1.5bn Rönnskär demo plant (280 kt/yr SCMentum) 2026–28. SCM emits <5% of cement CO2; exploration continues.
18 March 2026
Avantium reports 2025 full-year results
Phased start-up of the FDCA Flagship Plant progressed despite construction delays; €85M equity and amended financing secured; half the plant operational; full start-up targeted in 2026
17 March 2026
Perimeter Solutions: SOLBERG EVOLUTION 3% SFFF — first Newtonian fluorine‑free foam with FM approval
Mil‑Spec and ICAO Level B certified; UL‑162 approved for fixed sprinkler use; compatible with standard sprinkler hardware and aircraft surfaces; PFAS‑free, biodegradable; validated for ARFF
17 March 2026
Vioneo on the EU Single‑Use Plastics Directive
Calls for SUPD to clarify treatment of fossil-free plastics, align rules with decarbonisation goals, harmonise EPR and fee eco-modulation, and incentivise renewable-carbon supply chains.
17 March 2026
Kemira obtains PMRA approval in Canada for KemConnect DEX
Chlorine-free performic-acid wastewater disinfection; used in Paris 2024 wastewater works. Combines on-site generation, real-time monitoring and dosing algorithm. Canada rollout pending approvals
16 March 2026
Bilfinger earns fourth straight EcoVadis Gold with 83-point score
Ranks top 1% in industry, top 2% globally; SBTi-validated 2025 climate targets toward net-zero by 2050; EcoVadis scores: Env86, Labor79, Ethics89, Proc86; GHG -8% (S1&2), -4% (S3); LTIFR 0.18
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
16 March 2026
Terumo Aortic's Fenestrated TREO® Gains FDA Breakthrough Status
The FDA's Breakthrough Device Designation accelerates the review of Fenestrated TREO®, a custom stent-graft for complex abdominal aortic aneurysms, offering a tailored, minimally invasive solution.
16 March 2026
Petrobras to Acquire Full Ownership of Tartaruga Verde and Espadarte Fields
Petrobras will pay $450M to acquire Petronas' 50% stake in Tartaruga Verde and Espadarte fields, regaining full ownership. Completion awaits regulatory approval.
16 March 2026
Aptar's Nasal Delivery System in Phase II Study for SPONTAN® Spray
Aptar's nasal system aids LTR Pharma's SPONTAN® Phase II study, focusing on safety, tolerability, and pharmacokinetics for erectile dysfunction treatment.
16 March 2026
Neste Advocates Strong Anti-Fraud Measures in Biofuels Supply Chains
Neste emphasizes rigorous supplier audits, traceability, and collaboration to combat fraud in renewable raw materials, ensuring compliance and authenticity in its supply chains.
16 March 2026
Lilly's EBGLYSS Achieves Positive Phase 3 Results in Pediatric Atopic Dermatitis
EBGLYSS shows significant skin improvement and itch relief in children with moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints in Phase 3 ADorable-1 trial.
13 March 2026
MOL and Slovnaft File Complaint Against JANAF's Pricing Practices
JANAF's pricing is deemed excessive and unjustified, impacting energy supply security. MOL and Slovnaft have raised concerns with the European Commission over these practices.
13 March 2026
Petrobras Adjusts Diesel Prices
Diesel prices rise by R$ 0.38/liter for distributors. Federal tax exemptions and a subsidy program mitigate consumer impact.
13 March 2026
GSK's Arexvy RSV Vaccine Approved for Expanded Use in US Adults 18-49
FDA expands Arexvy's use to adults 18-49 at risk for severe RSV. Phase III trials show efficacy and safety. 17,000 hospitalizations annually in this age group.
13 March 2026
Petrobras Joins Diesel Subsidy Program
Petrobras' Board approves joining a diesel subsidy, pending regulatory review. The move aligns with its strategy to maintain market share and profitability without price volatility.
12 March 2026
Lhyfe Maintains Strong ESG Rating from Ethifinance
Lhyfe scored 88/100 in 2024 ESG performance, reflecting strong environmental efforts and energy independence, with improved ratings since 2022.
12 March 2026
Johnson & Johnson's TECNIS PureSee IOL Gains FDA Approval for Cataract Surgery
TECNIS PureSee IOL offers enhanced vision for cataract patients, reducing reliance on glasses and maintaining contrast sensitivity, with 97% reporting no bothersome visual disturbances.
11 March 2026
Port of Rotterdam: Demand Uncertainty Delays Hydrogen Terminal Investments
Investment in hydrogen terminals is stalled due to demand uncertainty, policy clarity, grid congestion, and infrastructure issues, with operations expected post-2030.
10 March 2026
BASF Expands Ultrason® P Portfolio for EU Food-Contact Compliance
Six new PPSU grades comply with EU regulations, enabling a smooth transition for manufacturers of high-temperature food-contact articles.
9 March 2026
Shell Sells Jiffy Lube and Premium Velocity Auto to Monomoy Capital Partners
Shell sells Jiffy Lube and Premium Velocity Auto for $1.3B, retaining other lubricant brands. A long-term supply agreement is included. Closing expected in H2 2026, pending approvals.
9 March 2026
Sinopec Leads Hydrogen Standardization in Energy Industry
A new committee aims to enhance hydrogen industry standards, drive innovation, and regulate the market, marking a key step for China's hydrogen energy sector.
9 March 2026
GSK and Alfasigma License Agreement for Linerixibat Rights
Alfasigma gains global rights to develop and market linerixibat for cholestatic pruritus in PBC. GSK to receive payments and royalties. Regulatory reviews are ongoing.
8 March 2026
Genentech Updates on Phase III persevERA Study in ER-Positive Breast Cancer
persevERA study showed no significant progression-free survival improvement, but giredestrant was well tolerated. Further studies planned with CDK4/6 inhibitors.
6 March 2026
TotalEnergies Releases Independent Review of Tilenga Project Land Acquisition in Uganda
The assessment confirms compliance with land acquisition standards. An action plan addresses livelihood restoration, support for vulnerable households, grievance management, and gender considerations.
6 March 2026
Genentech's Gazyva Reduces Lupus Disease Activity in Phase III Trial
Gazyva shows significant improvement in SLE symptoms, achieving a 76.7% response rate and doubling remission rates in a Phase III trial, as published in NEJM.
5 March 2026
Johnson & Johnson's TECVAYLI and DARZALEX FASPRO Approved by FDA for Relapsed Multiple Myeloma
FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma, offering a new treatment option as early as second line with improved safety and efficacy.
4 March 2026
MOL and Slovnaft File Complaint Against JANAF for Monopoly Abuse
JANAF delays crude oil supply, citing legal checks, despite EU sanctions compliance, causing supply issues for Central Europe. MOL seeks EU intervention for fair access and pricing.
4 March 2026
Sinopec Backs New National Greenhouse Gas Emission Database
The updated database includes methane emission factors for onshore facilities, aiding accurate greenhouse gas calculations and supporting emission reduction efforts in the oil and gas sector.
3 March 2026
Johnson & Johnson's Nipocalimab Gets FDA Fast Track for Lupus Treatment
Nipocalimab, an investigational therapy, aims to address unmet needs in lupus by reducing harmful IgG while preserving immune function, following positive Phase 2b results.
2 March 2026
Takeda's Rusfertide Receives FDA Priority Review
Rusfertide shows promise in controlling hematocrit and reducing symptoms in polycythemia vera, with FDA review based on positive Phase 3 and long-term study data.
← Previous
Next →
